Lonza Drops on Roche Drug Copy Testing Concerns: Zurich MoverBusinessweekTeva and Lonza have not started phase III trials for rituximab, a generic copy of Rituxan, Dirk Oehlers, a spokesman for Lonza, said by telephone. The company is evaluating how to…
Lonza Drops on Roche Drug Copy Testing Concerns: Zurich MoverBloombergTeva and Lonza have not started phase III trials for rituximab, a generic copy of Rituxan, Dirk Oehlers, a spokesman for Lonza, said by telephone. The company is evaluating how to mo…
Lonza et Teva examinent la voie à suivre pour l'homologation du RituximabRomandie.comBâle (awp) – Lonza veut clarifier la situation actuelle du développement de son produit "Rituximab" en raison de rumeurs et d'articles de presse p…
LONZA GROUP AG : Clarification on Biosimilar Activities4-tradersBasel, 05 October 2012 – Following several reports and rumors in the past few days in relation to the Biosimilar activities of the joint venture of Lonza and Teva, Lonza wants to clarify t…
Lonza und Teva prüfen weiter Wege zur Zulassung für das Biosimilar Rituximabfinanzen.chBasel (awp) – Lonza sieht sich aufgrund von Presseberichten und Gerüchten dazu veranlasst, die aktuelle Situation um die Entwicklung des Medikaments Rituximab kla…
Research and Markets: DRG Insight: Rheumatoid Arthritis (G7)The Herald | HeraldOnline.comBiologics from other drug classes – the interleukin-6 inhibitor tocilizumab (Roche/Chugai's Actemra/RoActemra), the selective costimulation modulator abatacept…
HaaretzTeva halts tests of cancer drug biosimilarHaaretzDeveloping a biosimilar generic version of Rituxan (rituximab) is a key goal of the joint venture that Teva, the biggest generic drugmaker in the world, formed in January 2009 with the Swiss compa…
XconomyCelgene antes up $35M, snags buyout option on VentiRx cancer workFierceBiotechThe first will be a combination study with docetaxel for ovarian cancer with the second–a combination with rituximab–aimed at head and neck cancer. For VentiRx the d…
Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord …San Francisco Chronicle (press release)… beta-1b; Novartis) Forecast; BG-12 (dimethyl fumarate; Biogen) Forecast; Aubagio (teriflunomide; Sanofi) Forecast; Laquinimod (Teva/…
The booming business in biosimilarsBusiness StandardThe current biosimilars portfolio of Dr Reddy's Laboratories constitutes of filgrastim, peg-filgrastim, rituximab and darbepeotin alfa, which have commercial presence in 13 emerging countries. “…